(EDAP) MKap $56M //Heilung für Prostatakrebs nahe US-Zulassung (Seite 82)
eröffnet am 01.10.13 22:36:23 von
neuester Beitrag 04.03.24 14:24:13 von
neuester Beitrag 04.03.24 14:24:13 von
Beiträge: 1.134
ID: 1.186.741
ID: 1.186.741
Aufrufe heute: 0
Gesamt: 147.329
Gesamt: 147.329
Aktive User: 0
ISIN: US2683111072 · WKN: 908548 · Symbol: EDA
6,7500
EUR
0,00 %
0,0000 EUR
Letzter Kurs 22.04.24 Tradegate
Neuigkeiten
27.03.24 · globenewswire  |
13.03.24 · globenewswire |
06.03.24 · globenewswire |
04.03.24 · globenewswire |
Werte aus der Branche Dienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6700 | +37,44 | |
| 2,2499 | +34,72 | |
| 0,6695 | +34,71 | |
| 1,4600 | +33,94 | |
| 1,9500 | +26,62 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9150 | -12,56 | |
| 1,2150 | -13,21 | |
| 31,40 | -14,21 | |
| 0,6300 | -30,00 | |
| 1,0100 | -42,29 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 47.386.602 von urpferdchen am 28.07.14 19:00:29Ich wollte auch schon raus........aber blieb dann doch......zum Glück sind
meine Biotechwerte nur lauter kleine Posis außer Paion.
Hat hier wer News?
meine Biotechwerte nur lauter kleine Posis außer Paion.
Hat hier wer News?
Antwort auf Beitrag Nr.: 47.386.584 von Nordenstam am 28.07.14 18:57:58Bin hier nicht investiert, aber noch in Aeterna.
Hält sich relativ gut.
Makler sammelt heute schon jede Menge 100-er Päckchen, ganz entspannt eines ums andere.
Ist ein sehr gutes Zeichen.
Für mich.
Hält sich relativ gut.
Makler sammelt heute schon jede Menge 100-er Päckchen, ganz entspannt eines ums andere.
Ist ein sehr gutes Zeichen.
Für mich.
Antwort auf Beitrag Nr.: 47.386.414 von teresas am 28.07.14 18:27:01Adherex hält sich bei 1,01 - 1,02 $ -
Aber EDAP von 4,80 auf 3,50 $ das ist krass - fast 30 % Minus in 3 Stunden - wer weiss wieviel tiefer es noch
geht.
ich habe verkauft zu 2,65 € - und schon steigt der Mist
Aber EDAP von 4,80 auf 3,50 $ das ist krass - fast 30 % Minus in 3 Stunden - wer weiss wieviel tiefer es noch
geht.
ich habe verkauft zu 2,65 € - und schon steigt der Mist
Zitat von teresas: 2. Rohrkrepierer nach Adherex von biohero
Bleibt nur noch Aeterna
Schäm Dich Mädel....schau bitte mal wann biohero Edap empfohlen hat....und Adherex ebenso....beide sind durch die Spekulation seit seiner -- übrigens sehr informativen -- Empfehlung um einiges über 100% gestiegen.
...wenn man zu blöd zum verkaufen ist sollte man seine Unfähigkeit wenigstens nicht anderen zuschreiben.
Und sei jetzt nicht angesäuert....ich bin ja selbst zu blöd
Trading Spotlight
Antwort auf Beitrag Nr.: 47.386.476 von Aktiengeier_1 am 28.07.14 18:39:09Das ist alt, vom 27 Juno
EDAP Completes FDA Inspection of Manufacturing Site
FDA Inspector Reported no Findings From the Scheduled Facility Audit
GlobeNewswire EDAP TMS SA
June 27, 2014 8:30 AM
EDAP Completes FDA Inspection of Manufacturing Site
FDA Inspector Reported no Findings From the Scheduled Facility Audit
GlobeNewswire EDAP TMS SA
June 27, 2014 8:30 AM
Antwort auf Beitrag Nr.: 47.386.476 von Aktiengeier_1 am 28.07.14 18:39:09Sorry was altes erwischt.........Mist
Mon, Jul 28, 2014, 12:35 PM
EDAP Completes FDA Inspection of Manufacturing Site
FDA Inspector Reported no Findings From the Scheduled Facility Audit
GlobeNewswire EDAP TMS SA
June 27, 2014 8:30 AM
LYON, France, June 27, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, today announced that the U.S. Food and Drug Administration (FDA) concluded its routine inspection of EDAP's manufacturing site with no findings nor issuance of Form 483 observations.
Marc Oczachowski, EDAP's Chief Executive Officer, commented, "This is another important step in the FDA PMA process for our Ablatherm-HIFU technology. It confirms and validates EDAP's ability to comply with high engineering, manufacturing and quality standards. In parallel, our team remains fully focused on preparing for the July 30, 2014 advisory committee meeting."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm(R) for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA. In February 2013, the Company introduced a new innovative HIFU device, the Focal One(R) dedicated to focal therapy of prostate cancer. Focal One(R) is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith(R) range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.
http://finance.yahoo.com/news/edap-completes-fda-inspection-…
EDAP Completes FDA Inspection of Manufacturing Site
FDA Inspector Reported no Findings From the Scheduled Facility Audit
GlobeNewswire EDAP TMS SA
June 27, 2014 8:30 AM
LYON, France, June 27, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, today announced that the U.S. Food and Drug Administration (FDA) concluded its routine inspection of EDAP's manufacturing site with no findings nor issuance of Form 483 observations.
Marc Oczachowski, EDAP's Chief Executive Officer, commented, "This is another important step in the FDA PMA process for our Ablatherm-HIFU technology. It confirms and validates EDAP's ability to comply with high engineering, manufacturing and quality standards. In parallel, our team remains fully focused on preparing for the July 30, 2014 advisory committee meeting."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm(R) for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA. In February 2013, the Company introduced a new innovative HIFU device, the Focal One(R) dedicated to focal therapy of prostate cancer. Focal One(R) is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith(R) range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.
http://finance.yahoo.com/news/edap-completes-fda-inspection-…
Das ist schon eine Hausnummer, von 6$ runter auf 3,80$, innerhalb weniger Handelstage. 
Antwort auf Beitrag Nr.: 47.385.816 von urpferdchen am 28.07.14 17:03:16kurs drücken ist zwar doof aber ich hoffe mal du hast recht sonst wird das morgen ein schöner schlag ins gesicht 
Durchsuchen
